Untitled case

I'll research this docket and patent before drafting.

The patent is Cetus/Roche's Taq polymerase patent, and one result points to a 2003–2004 E.D. Va. case involving Promega, Applera and Roche. Let me verify the docket.

Case overview: Promega Corp. v. Hoffmann-La Roche Inc. & Applied Biosystems/Applera Corp., No. 1:03-cv-01447 (E.D. Va.)

A necessary correction to the premise first. The best available evidence indicates that E.D. Va. No. 1:03-cv-01447 was not a patent infringement suit. It was a False Claims Act / fraud action brought by Promega Corporation against Hoffmann-La Roche Inc. (with Roche Molecular Systems) and Applied Biosystems Inc./Applera Corp., premised on the theory that the defendants had made false statements to the U.S. government in procuring and enforcing U.S. Patent No. 4,889,818, and that the government's Taq/PCR licensing payments were therefore recoverable. The Milwaukee Business Journal's August 2004 report describes Judge Claude M. Hilton dismissing the case, for the second time, for failure to state a fraud claim, with Promega announcing an appeal to the Fourth Circuit; The PharmaLetter (Aug. 29, 2004) confirms the Fourth Circuit was to decide "the right of the USA to recover losses on payments made to… Roche and its partner, US firm Applera Corp… under the False Claims Act." Promega sought "potentially hundreds of millions of dollars in licensing payments made by the U.S. government." Applera's 2005 Form 10-K confirms the case was filed in E.D. Va. and "dismissed in August 2004 for, among other reasons, failure to state a claim." Caveat: I could not pull the PACER docket itself; the linkage of the facts above to docket number 1:03-cv-01447 rests on the 2003 filing year, the E.D. Va. venue, the identical parties, and the '818 patent — strong but not docket-verified. I also could not verify the Fourth Circuit's disposition.

Parties. All three are operating companies in the life-sciences tools sector — there is no NPE/PAE, university, or troll component here. Promega Corp. (Madison, Wis.) is a reagents and molecular-biology tools manufacturer; notably, Promega had been the licensee of the '818 patent under a 1990 Cetus license, which is why it was the party with contractual knowledge of the patent's prosecution history. Hoffmann-La Roche Inc. (U.S. subsidiary of the Basel-based group) and Roche Molecular Systems, Inc. (Pleasanton, Calif.) held the '818 patent, which Cetus Corporation assigned to Roche in December 1991 along with its PCR business. Applied Biosystems / Applera Corp. (Foster City, Calif.) was Roche's PCR joint-venture partner and the leading thermal-cycler instrument maker — the counterparty in the long-running Cetus/Perkin-Elmer PCR venture. The "accused technology" framing does not fit: the subject matter was native Thermus aquaticus (Taq) DNA polymerase and PCR-related products and licenses, including Taq sold to U.S. government laboratories, not an infringing product per se.

The patent and why the case existed. U.S. 4,889,818, "Purified thermostable enzyme," filed June 17, 1987, issued Dec. 26, 1989, with an August 1986 priority date and only three claims (now expired). Claim 1 is a product claim to purified Taq DNA polymerase defined by gel mobility and an estimated molecular weight of 86,000–90,000 daltons relative to a phosphorylase B standard; claims 2–3 cover the native and recombinantly produced enzyme. Its technical significance is that Taq's thermostability is what made automated PCR cycling practical — the enzyme is the reagent that made PCR a commercial industry. The E.D. Va. action was a downstream consequence of Hoffmann-La Roche, Inc. v. Promega Corp., 323 F.3d 1354 (Fed. Cir. Mar. 31, 2003), which affirmed most of the district court's inequitable conduct findings (the prophetic "Example VI" written in the past tense, and the fidelity/template-dependence representations) while reversing on molecular weight; on remand the N.D. Cal. court held the '818 patent unenforceable, 319 F. Supp. 2d 1011 (N.D. Cal. 2004). Promega then argued, in Virginia, that enforcing a patent procured through those misrepresentations against the government was itself a false claim.

Procedural posture and venue. E.D. Va., Alexandria Division (the "1:" docket prefix), before Judge Claude M. Hilton; complaint filed in 2003, dismissed with leave to amend, and dismissed again in August 2004, followed by a notice of appeal to the Fourth Circuit. Venue made sense for a government-payments fraud theory: Alexandria sits adjacent to Washington, D.C., where the federal agencies that purchased Taq and PCR reagents and the Department of Justice (which must decide whether to intervene in an FCA relator action) are located; E.D. Va. was also at the time the country's fastest docket, the "rocket docket." Whether Promega specifically relied on a venue provision tied to government contracting, or on Roche/Applera's contacts with Virginia, is not something I could source.

Why it matters. Three reasons. (1) It is the closing act of the Taq patent wars — the rare case in which a foundational biotechnology patent (PCR/Taq, a Nobel-adjacent technology) was held unenforceable for inequitable conduct, a holding that Roche II made a standard citation in inequitable-conduct doctrine and that Judge Newman dissented from as reviving a "plague" of inequitable-conduct charges. (2) It tested an aggressive FCA–patent interface theory: that a fraudulently procured patent used to extract federal payments creates False Claims Act liability, which would have opened a qui tam route to treble damages in patent procurement cases — a theory the district court rejected on the pleadings. (3) It sits within a cluster of follow-on litigation: the D.D.C. Walker Process antitrust class action, Molecular Diagnostics Laboratories v. Hoffmann-La Roche/Applera (Judge Henry H. Kennedy, Jr.), which survived dismissal and settled in 2008 for $33 million plus $11 million in fees; and the underlying Roche–Promega contract/infringement litigation, which settled in September 2005. Market context: Taq reagent pricing and Roche/Applera's PCR licensing program were a live access-to-research-tools controversy in the early 2000s, which is exactly the backdrop that made both the FCA and antitrust theories plausible to plaintiffs.

Verification gaps to note in the final product: (a) docket-level confirmation of case number 1:03-cv-01447 against the Promega/Roche/ABI FCA action; (b) the Fourth Circuit's ruling on the appeal; (c) named counsel; (d) whether Applera was named as Applera Corp. or only Applied Biosystems Inc. in the E.D. Va. caption. None of these should be stated without a PACER or opinion citation.

I'll research this case and the patent systematically.

Found a strong lead — this appears to be a False Claims Act (qui tam) action, not a conventional infringement suit. Let me verify.

Bottom line up front

The case behind docket No. 1:03-cv-01447 (E.D. Va.) is not a patent infringement action, and the earlier case-summary note that "parties, patent(s) asserted, and outcome could not be confirmed" can now be corrected.

It is Promega Corp., et al. v. Hoffmann-LaRoche, et al., No. 1:03-cv-01447-CMH-TCB (E.D. Va., Alexandria Div.) — a False Claims Act qui tam / patent-misconduct action in which Promega, as relator on behalf of the United States, sought to recover roughly $1 billion in government payments for Taq DNA polymerase allegedly procured through Roche's enforcement of U.S. Patent No. 4,889,818 ("Purified Thermostable Enzyme," the native/recombinant Taq polymerase patent issued 1989-12-26 to Cetus, later sold to Roche). Judge Claude M. Hilton presided; Magistrate Judge Theresa C. Buchanan is the "TCB" in the suffix.

The case was dismissed with prejudice in August 2004 for failure to state a claim, after an earlier June 2004 dismissal with leave to amend, and Promega announced an appeal to the Fourth Circuit. The '818 patent itself had already been held unenforceable for inequitable conduct in the parallel Northern District of California litigation, a ruling the Federal Circuit largely affirmed in 2003 and the district court finalized on remand in May 2004.

---

1. Filing and initial pleadings

Parties. Plaintiffs/relators: Promega Corporation (Madison, WI) and individual relators on its behalf (the individual relators' names are not confirmed in the sources I could access). Defendants: Hoffmann-La Roche Inc., Roche Molecular Systems, Inc., and Applera Corp./Applied Biosystems (Roche's Taq licensing partner). Roche's counsel of record publicly identified: Ray Mullady, Orrick, Herrington & Sutcliffe LLP.

Theories pleaded (from Promega's own public description of the complaint):

• Payment of royalties for Taq under the '818 patent, which had been obtained by inequitable conduct before the PTO;
• Anticompetitive tying of Taq sales to other products;
• Deceptive licensing practices; and
• Predatory threats of litigation.
• Relief: treble damages on the government's behalf plus the FCA's $10,000 per-claim civil penalty.

Note on an inconsistency I could not resolve: An Applied Biosystems press release (Aug. 2004) states that "Promega originally filed this case on April 10, 2000," whereas Nature reports a 2003-11-13 filing and the docket number is a 2003 term. The most likely explanation is an earlier sealed qui tam filing (April 2000) followed by a re-filed/continued 2003 action, but I could not verify this from a docket. Treat the 2000 date as unconfirmed.

Answers/counterclaims: No answer or counterclaim is reflected in the public docket record I could retrieve; the case was resolved at the pleading stage, before defendants were put to an answer.

2. Pre-trial motions of substance

• Rule 12(b)(6) motion to dismiss (granted, June 2004). Judge Hilton dismissed the original complaint, holding Promega "had not been able to plead the basic facts required to show a violation of law." (bionity.com, 2004-08-24, quoting Roche's counsel; Limsforum/Applied Biosystems release.)
• Amended complaint (July 2004). Promega amended; Roche's counsel characterized it as offering "no new information" and "recycl[ing] those claims already rejected by the Virginia court."
• Second motion to dismiss (granted, Aug. 2004). The court dismissed the amended complaint on multiple grounds, holding Promega failed to state a valid claim and rejecting the theory that Roche/ABI had made false claims to the government in connection with Taq sales. Orrick's Mullady: "Promega failed to identify any false statements made by Roche to the Government, or any false charges ever submitted by Roche." (bionity.com 2004-08-24; Limsforum.)
• Discovery/protective-order skirmishing. Docket reflects a motion for a protective order by Hoffmann-La Roche et al., with the hearing continued from 2004-07-30 to 2004-08-06 before Mag. J. Buchanan. (plainsite docket, No. 1:03-cv-01447-CMH-TCB.)
• Plaintiffs' motion for partial summary judgment (filed, never decided). Docket entry on plainsite: an order granting Roche's motion for extension of time to respond to plaintiffs' motion for partial summary judgment and continuing the hearing; defendants were given until eleven days after the court rules on their motions to dismiss to oppose, and plaintiffs were to re-notice the MSJ. The August 2004 dismissal mooted the summary-judgment motion.
• No motion to transfer, no stay pending IPR/PGR, and no Markman proceeding — the case never reached claim construction, and no IPR was possible (see §7).

3. Claim construction

None. The case terminated at the pleading stage; there is no Markman order, no claim-construction briefing, and no construction of any '818 claim term.

4. Discovery milestones of strategic significance

Discovery was never meaningfully joined. The only recorded discovery event is the protective-order motion practice in July–August 2004 (hearing reset to 2004-08-06) and the

I'll research this case. Let me start with several searches.

Bottom line

I could not identify any counsel of record for plaintiffs in Untitled (No. 1:03-cv-01447, E.D. Va.). No attorney names should be reported for this case on the current record, because nothing I found ties any named lawyer to this docket. Per your instruction not to invent attorneys, I am reporting the negative finding rather than a reconstructed counsel list.

What I searched and what came back

So: no docket sheet, no opinion, no PACER extract, and no press coverage of this specific case was located. I also could not verify that counsel ever appeared — the case may have been dismissed before appearance, transferred/consolidated, or the Google Patents litigation entry may itself be an unverified or mis-keyed record (the existing case summary already flags "parties, patent(s) asserted, and outcome could not be confirmed").

What is verifiable — the patent and its real enforcement history

This context is solid and useful for framing, but it is not counsel-of-record data for 1:03-cv-01447:

• US 4,889,818 ("Purified thermostable enzyme") issued Dec. 26, 1989 to Cetus inventors David Gelfand, Susanne Stoffel, Frances Lawyer, and Randall Saiki; it claims purified Thermus aquaticus (Taq) DNA polymerase and became the cornerstone of Roche's PCR/Taq licensing program after the Cetus–Roche/Hoffmann-La Roche transaction. (Google Patents; EPO family member EP 0 258 017.)
• The principal U.S. enforcement proceeding was Roche v. Promega in the N.D. Cal., where the district court held the '818 patent unenforceable for inequitable conduct (eight misrepresentations/omissions), a ruling largely affirmed by the Federal Circuit in 2003 — reported, as I recall, at 323 F.3d 1354 (Fed. Cir. 2003); I flag that citation as recalled rather than confirmed in this session and it should be Shepardized before use.
• Parallel antitrust follow-on: Molecular Diagnostics Lab v. Hoffmann-La Roche (D.D.C., complaint filed 2002, motion to dismiss denied Dec. 2005), which pleaded Roche's enforcement of the '818 patent – per Patently-O's Dec. 2005 coverage.
• The EPO revoked the counterpart EP 0 258 017 in May 2001 on Chien/Kaledin prior art.

Given that the '818 patent was held unenforceable in 1999–2003, a 2003 E.D. Va. filing asserting it would be unusual — which raises the possibility that the Google Patents entry reflects a case in which the '818 patent was pleaded only as background, as a counterclaim reference, or in an antitrust/declaratory-judgment posture, rather than as an asserted patent.

Recommended verification path (nothing here is a substitute for the docket)

1. PACER direct pull of vaed docket 1:03-cv-01447 (NEF/docket text; party and attorney listings). Pre-2005 E.D. Va. entries are often abbreviated, and ECF attorney appearances may be sparse.
2. Clerk's office, E.D. Va. (Alexandria division) — request the paper docket/archive if the electronic record is incomplete; 2003 filings sometimes predate full ECF capture.
3. RECAP/CourtListener docket lookup by case number, and Docket Navigator / Lex Machina / RPX party-name search on 4,889,818, which index patent dockets independently of PACER coverage.
4. Google Patents litigation tab for US4889818 — inspect the underlying entry for the party and source it was harvested from; it often cites a bare court/case number with no docket support, which would explain the unconfirmed status.
5. If a Roche entity is confirmed as plaintiff, counsel would most likely have come from Roche's in-house litigation group plus outside counsel then handling the '818 docket (e.g., the firms in Roche v. Promega), but I will not name those lawyers as counsel here absent the appearance record.

If you can supply the PACER docket text or the party names, I can build the full counsel table — name, role, firm/office, and patent-litigation history — with sourcing for each entry.

I'll research this case systematically, starting with the patent and the docket.

Let me identify the patent first, which will point to the parties.

US 4,889,818 appears to be the Roche/Cetus native Taq DNA polymerase patent. Let me find the actual docket.

Bottom line

I was unable to identify any counsel of record for the defendant(s) in this action, and I will not guess. The searches I was able to run did not surface the docket sheet, a complaint, an opinion, or even the party names for E.D. Va. No. 1:03-cv-01447. Because I could not establish who the defendant is, any attorney name I gave you would be fabricated. Please treat this section as an open item rather than a finding.

What I could confirm

The patent's identity and owner. US 4,889,818 is generally understood to be the native Thermus aquaticus (Taq) DNA polymerase patent associated with Roche/Cetus — i.e., PCR enabling technology, not a typical E.D. Va. patent-plaintiff asset. I found one contemporaneous secondary source connecting the number to that technology and to Roche litigation:

• BioCentury (reporting on N.D. Cal. proceedings and Roche's suit against Promega over breach of a Taq supply contract and infringement of "U.S. Patent No. 4,889,818 covering native Thermus aquaticus (Taq) DNA polymerase," including a ruling that the patent was unenforceable for inequitable conduct): https://www.biocentury.com/article/64213

That source is about a Northern District of California case, not the E.D. Va. action. It is useful only because it tells you the technology and the likely patent holder, which should sharply narrow the candidate pool for the 2003 Virginia filing.

What I could not confirm. Despite searching for the case number, the patent number in combination with the district, and the patent in combination with 2003 and E.D. Va., I found no docket entry, complaint, opinion, press report, or Law360/Reuters item. The existing case summary's statement that "parties, patent(s) asserted, and outcome could not be confirmed" therefore stands unchanged on the record available to me. I also cannot say whether the case was an infringement action, a declaratory judgment action, or a license/contract dispute that merely touched the patent.

Why the counsel question is unanswerable as posed

Counsel of record in a 2003 E.D. Va. case would be documented in the CM/ECF docket (entries 1 onward, plus any notices of appearance). Without the docket I cannot distinguish lead from local counsel — which matters a great deal in this district, where out-of-state patent plaintiffs routinely retain Virginia local counsel under E.D. Va. Local Rule 83.1. I have no basis to say whether any defendant had appeared, whether the case was dismissed on a motion before appearance, or whether it settled.

How to close this out (recommended next steps)

1. PACER Case Locator / E.D. Va. CM/ECF — pull the full docket for 1:03-cv-01447. Pre-2005 E.D. Va. filings are in CM/ECF but sometimes require a archive pull; the docket header alone will give you the caption and thus the defendant entities.
2. CourtListener RECAP — free mirror; older E.D. Va. criminal/civil dockets are spotty, which likely explains my null result.
3. Google Patents "Litigation" tab for US 4,889,818 — the source the existing summary relies on; it should list the caption alongside the 2003 E.D. Va. entry.
4. Free secondary trackers — RPX Insight, Unified Patents portal, Darts-IP, and Bloomberg Law's docket search often carry 2003 captions that free search engines do not index.
5. Once the caption is known, cross-check counsel via the Virginia State Bar member search and the E.D. Va. CM/ECF attorney roll rather than relying on firm websites.

If you can supply the caption or a single docket entry (even "Doc. 1" or the defendant's name), I can run the counsel identification immediately and will cite the specific entries.